Decision Diagnostics (OTC: DECN) “Game Changer” products for $25 billion diabetes monitoring market

Keith Berman, CEO, Decision Diagnostics



Keith Berman, CEO, Decision Diagnostics








Decision Diagnostics (OTC: DECN) CEO Keith Berman discusses the company’s products targeting the $25 billion global diabetes monitoring market, and the company’s path to achieving $100 million+ revenues within next 2 years.

Topics discussed include:

  •  DECN’s products which offer competitive advantages including greater accuracy, and cost saving of about 50%. 
  • New product pipeline, including a “game changer” launching in 2019
  • FDA filings update
  • Update on JNJ litigation
  • Veterinary products update
  • And More

Investor Fact Sheet

Decision Diagnostics

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.